Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis.
BACKGROUND
Previous studies have demonstrated survival benefits for local treatment in solitary metastatic non-small cell lung cancer (NSCLC).This study aimed to investigate the effect of local surgery for NSCLC with pulmonary oligometastasis.


METHODS
This study included 21 patients of NSCLC with pulmonary oligometastasis between January 2003 and December 2013, which were divided into two groups, group A (11 cases) for local surgery and group B (10 cases) for systematic chemotherapy, compared the median survival time (MST) and 5-year survival rate between the two groups, and analyzed the impact of the pathological types, the TNM and pN stage of primary tumor, the site, and the mode and number of oligometastatic nodule on group A.


RESULTS
The MST of group A and B were 37 and 11.6 months respectively, 5-year survival rates were 18.2 and 9.1% respectively (p < 0.05). Patients with single nodule, oligo-recurrence, primary tumor of pN0, TNM stage I or II obtained higher survival rate than those with multiple nodules, sync-oligometastases, pN1-2, stage III or IV in group A (p < 0.05). There was no significant survival time difference among pathological types of primary tumor and oligometastatic site (p > 0.05).


CONCLUSIONS
Local surgery significantly prolonged the overall survival time and 5-year survival rate of primary NSCLC with pulmonary oligometastasis.
Department of Cardiothoracic Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Jinyuan
J
He
Department of Cardiothoracic Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yun
Y
Li
Department of Cardiothoracic Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Jun
J
An
Department of Cardiothoracic Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Liu
L
Hu
Department of Cardiothoracic Surgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. junhangzhang1111@163.com.
Junhang
J
Zhang
D000230:Adenocarcinoma / Q000556:secondary / Q000601:surgery*; D000328:Adult; D000368:Aged; D018287:Carcinoma, Large Cell / Q000556:secondary / Q000601:surgery*; D002289:Carcinoma, Non-Small-Cell Lung / Q000556:secondary / Q000601:surgery*; D002294:Carcinoma, Squamous Cell / Q000556:secondary / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000556:secondary / Q000601:surgery*; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
Non-small cell lung cancer; Oligo-recurrence; Oligometastasis; Sync-oligometastases